可切除胰腺癌微创与开放左胰腺切除术长期结果:DIPLOMA随机试验
IMPORTANCE: The DIPLOMA trial showed comparable radical resection rates after minimally invasive left pancreatectomy (MILP) and open left pancreatectomy (OLP) in patients with upfront resectable pancreatic cancer.…
要点
- MILP与OLP长期总生存和无病生存无显著差异。
- 两组辅助治疗接受率(70% vs 72%)和启动时间(59 vs 56天)相当。
- 长期随访证实MILP在可切除胰体尾癌中肿瘤学安全。
核心结论
- 在upfront可切除胰腺癌患者中,MILP与OLP的长期肿瘤学结局无显著差异,证实了MILP的肿瘤学安全性。
研究设计与样本
- 随机、患者盲法和病理学家盲法的国际多中心试验,2018至2021年在12个国家35个中心开展,随访至少36个月。
- 共纳入258例upfront可切除胰体尾导管腺癌患者,随机分为MILP组(131例)和OLP组(127例)。
主要发现
- 中位随访38(IQR 36-46)个月,134例(52%)死亡,127例(55%)出现疾病复发。
临床怎么用
- 对于upfront可切除的胰体尾导管腺癌,MILP可作为与OLP相当的肿瘤学安全选择。
- 在决定微创入路时,无需担心其对长期生存、复发或辅助治疗实施的不利影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The DIPLOMA trial showed comparable radical resection rates after minimally invasive left pancreatectomy (MILP) and open left pancreatectomy (OLP) in patients with upfront resectable pancreatic cancer. Data on long-term overall survival (OS) and disease-free survival (DFS) are currently lacking, but are required before the oncological efficacy of MILP can be confirmed. OBJECTIVE: To determine the long-term oncological outcome, including OS and DFS, of MILP vs OLP in patients with upfront resectable left-sided pancreatic cancer in the DIPLOMA trial. DESIGN, SETTING, AND PARTICIPANTS: The randomized, patient-blinded and pathologist-blinded DIPLOMA trial was conducted between 2018 and 2021, with a follow-up duration of at least 36 months. It was a multicenter international trial that took place in 35 centers in 12 countries worldwide. Patients with upfront resectable pancreatic ductal adenocarcinoma of the body or tail of the pancreas were included. INTERVENTIONS: Participants were randomly assigned to undergo MILP (laparoscopic and robotic) or OLP. Patients were blinded for the surgical approach. MAIN OUTCOMES AND MEASURES: Main outcomes included OS and DFS. Other outcomes include receipt of adjuvant therapy and time to start of adjuvant therapy. RESULTS: Between May 2018 and May 2021, 258 patients were randomized to the MILP (131 patients) and OLP (127 patients) groups. After a median follow-up of 38 (IQR 36-46) months, 134 patients (52%) had died and 127 patients (55%) experienced disease recurrence. OS did not differ significantly between the MILP and OLP groups (median, 32 vs 34 months; stratified hazard ratio, 1.02; 95% CI, 0.72-1.44; P = .92). Also, DFS did not significantly differ between the MILP and OLP groups (median, 21 vs 17 months; stratified hazard ratio, 0.96; 95% CI, 0.68-1.35; P = .81). Adjuvant therapy was administered in 79 patients after MILP (79 of 113 [70%]) and 79 patients after OLP (79 of 110 [72%]) (P = .63). Time to adjuvant therapy was comparable between groups (median 59 vs 56 days; P = .92). CONCLUSIONS AND RELEVANCE: In this long-term follow-up of the randomized DIPLOMA trial in patients with upfront resectable pancreatic cancer, oncological outcomes after MILP and OLP did not differ significantly, confirming the oncological safety of MILP. TRIAL REGISTRATION: International Standard Registered Clinical/Social Study Number Registry Identifier: ISRCTN44897265.
引用
- Bruna CL, van Hilst J, Korrel M, et al. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. JAMA Surg. 2025. PMID: 41060640. doi:10.1001/jamasurg.2025.4054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。